<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04405206</url>
  </required_header>
  <id_info>
    <org_study_id>BJCC-R01</org_study_id>
    <nct_id>NCT04405206</nct_id>
  </id_info>
  <brief_title>Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer</brief_title>
  <acronym>BJCC-R01</acronym>
  <official_title>Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for MRI Stratified Low-risk Rectal Cancer: a Multi-center, Prospective, Single-arm Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To investigate the safety and efficacy of organ preservation (OP) with watch-and-wait&#xD;
      strategy (W&amp;W) or local excision (LE) in MRI stratified low-risk rectal cancer treated by&#xD;
      total neoadjuvant treatment. Meanwhile we will look into the role of ctDNA in the prediction&#xD;
      of regrowth and metastasis in the wait and wait process.&#xD;
&#xD;
      Methods: Low-risk rectal cancer with following MRI features are recruited: mid-low tumor,&#xD;
      mrT2-3b, MRF(-), EMVI(-), differentiation grade 1-3. Patients will receive IMRT 50.6Gy/22f&#xD;
      with concurrent capecitabine and 4 cycles of consolidation CAPEOX. Patients with cCR/near-cCR&#xD;
      were recommended for 'watch &amp; wait' approach or local excision (LE). The OPR and sphincter&#xD;
      preservation rate (SPR) at 2 years will be analyzed.&#xD;
&#xD;
      As the extension of PKUCH-R01, BJCC-R01 trial will upgrade to a multi-center research&#xD;
      enrolled 3 other colorectal center in Beijing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neoadjuvant chemoradiotherapy (nCRT), total mesorectal excision and adjuvant chemotherapy&#xD;
      comprise the standard treatment for locally advanced rectal cancer, following which 15-30%&#xD;
      patients achieved pathological complete response need to receive the removal of rectum&#xD;
      without residual tumor and suffer significant functional impairment even after sphincter&#xD;
      preservation. Adjuvant chemotherapy is also questioned for its benefit for prolonged survival&#xD;
      through the data from various studies. More evidence demonstrated that organ-preservation&#xD;
      (e.g. non-operative management or local excision) for patients with clinical complete&#xD;
      response (cCR) or near-cCR following nCRT had similar survival when compared with those&#xD;
      received standard care.&#xD;
&#xD;
      This study is designed to investigate the efficacy of neoadjuvant intensity modulated nCRT&#xD;
      with concurrent capecitabine plus consolidation CapeOX for T2/DWI/Enhanced MRI defined&#xD;
      cT2-T3b mid-low rectal cancer without threatening mesorectal fascia or extramural vascular&#xD;
      invasion (EMVI) or mrN2 disease.&#xD;
&#xD;
      According to the response to treatment evaluated by multi-modal assessment including digital&#xD;
      exam, T2/DWI/Enhanced MRI, endoscopy and serum CEA test, patients will receive tailored&#xD;
      operative management like local excision or total mesorectal excision, or non-operative&#xD;
      management. Intention to treatment was also allowed in this study.&#xD;
&#xD;
      Firstly, the investigators will observe the organ preservation rate at 2 years. Endpoints for&#xD;
      organ-preservation like non-regrowth DFS, stoma-free survival and other conventional survival&#xD;
      outcomes (DFS, OS) would be further collected. The short-term and long-term QoL will be&#xD;
      measured in all patients.&#xD;
&#xD;
      . Our baseline data showed the 48% of locally advanced rectal cancers could be downstaged to&#xD;
      stage ypT0-2N0 following IMRT with concurrent capecitabine. We hypothesize that at least 24%&#xD;
      of rectal cancers could be candidates for LE or NOM after IMRT and the rectum preservation&#xD;
      rate will increase to 40% in low-risk rectal cancers by LE or NOM following IMRT plus&#xD;
      consolidation CapeOX at 2 years. As a superiority design, this study need to recruit 64&#xD;
      patients to test this hypothesis, with 85% power (exact binomial test for proportions, alpha&#xD;
      = 5 %, one-sided), If the number of responses is 22 or more, the hypothesis that P &lt;= 0.240&#xD;
      is rejected. We anticipate about 10 % loss to follow-up, so we will recruit an additional 8&#xD;
      patients and the study will recruit 72 patients in all.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OPR(organ preservation rate)</measure>
    <time_frame>3 year</time_frame>
    <description>Proportion of patients who achieved cCR or near cCR after neoadjuvant treatment and received watch and wait approach or local excision</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NR-DFS(Non-regrowth disease free survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Within 3 years after receiving the neoadjuvant treatment, the time patient in status free of death, local recurrence after radical resection or distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SFS(stoma-free survival)</measure>
    <time_frame>3 year</time_frame>
    <description>Within 3 years after receiving the neoadjuvant treatment, the time patient in status free of stoma</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Rectum Cancer</condition>
  <arm_group>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <description>Group A:Clinical complete response (cCR) Patients who achieve cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Nonoperative Management(NOM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <description>Patients who achieve near-cCR when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation CapeOX(Capecitabine+Oxaliplatin) will receive Local Excision(LE) or Nonoperative Management(NOM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <description>Patients with residual tumor when restaged by DRE-Endoscopy-MRI-CEA at 16 weeks following intensity modulated radiotherapy(IMRT) plus consolidation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>OXA 130mg/m2</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <other_name>OXA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Cape 1000mg/m2</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <other_name>Cape</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity modulated radiotherapy</intervention_name>
    <description>IMRT 50.4Gy/22f</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DRE-Endoscopy-MRI-CEA</intervention_name>
    <description>examination process in follow up</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonoperative Management</intervention_name>
    <description>Watch and Wait</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <other_name>NOM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local excision</intervention_name>
    <description>For ymriT1N0 and near-cCR patients，LE is optional.</description>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <other_name>LE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Standard TME surgery openly or laporoscopically</description>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <other_name>TME</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Quality of Life Questionnaires</intervention_name>
    <description>QLQ C30 and QLQ CR29</description>
    <arm_group_label>Group A:Clinical complete response (cCR)</arm_group_label>
    <arm_group_label>Group B:Near-cCR</arm_group_label>
    <arm_group_label>Group C:Residual tumor</arm_group_label>
    <other_name>QLQ</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FFPE and peripheral blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Rectal cancer patient who receives primary care in Beijing Cancer Hospital will be selected&#xD;
        as the candidate for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. the age is more than 18 years old and less than 85 years old;&#xD;
&#xD;
          -  2. ECOG score of physical condition is 0-1;&#xD;
&#xD;
          -  3. adenocarcinoma of rectum confirmed by pathology; differentiated into Grade 1-3,&#xD;
             i.e. high, medium and low differentiated adenocarcinoma&#xD;
&#xD;
          -  4. the distance from the lower edge of the tumor to the anal edge ≤ 12cm (endoscopy)&#xD;
             or to the anorectal ring (ARJ) ≤ 8cm;&#xD;
&#xD;
          -  5. the initial MRI was T2 / T3a / T3B, with negative EMVI and negative CRM. There was&#xD;
             no lymph node metastasis outside the ilium, general ilium, obturator and abdominal&#xD;
             aorta&#xD;
&#xD;
          -  6. the maximum diameter of tumor ≤ 4cm or the circumferentially invasive area is less&#xD;
             than 1 / 3 of intestinal circumference&#xD;
&#xD;
          -  7. no evidence of distant metastasis;&#xD;
&#xD;
          -  8. no history of pelvic radiotherapy;&#xD;
&#xD;
          -  9. no history of surgery or chemotherapy for rectal cancer;&#xD;
&#xD;
          -  10. systemic infection without antibiotic treatment;&#xD;
&#xD;
          -  11. blood routine test: neutrophil absolute value &gt; 1.5 × 10 9 / L, HGB &gt; 10.0 g / dl,&#xD;
             PLT &gt; 100 × 10 9 / L;&#xD;
&#xD;
          -  12. blood biochemistry: total bilirubin ≤ 1.5 x ULN, AST ≤ 3 x ULN, ALT ≤ 4 x ULN;&#xD;
&#xD;
          -  13. the patient read and signed the informed consent of the study and agreed to&#xD;
             participate in the study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. recurrent rectal cancer;&#xD;
&#xD;
          -  2. initial local non resectable rectal cancer (no possibility of R0 whole block&#xD;
             resection);&#xD;
&#xD;
          -  3. the creatinine level is 1.5 times higher than the upper limit of normal value;&#xD;
&#xD;
          -  4. have a history of pelvic radiotherapy;&#xD;
&#xD;
          -  5. the patients could not tolerate the enhanced MRI;&#xD;
&#xD;
          -  6. malignant tumors whose survival rate in the past 5 years is significantly lower&#xD;
             than that of rectal cancer in our center (excluding well treated basal cell carcinoma,&#xD;
             skin squamous carcinoma, small renal carcinoma, breast cancer and thyroid papillary&#xD;
             carcinoma);&#xD;
&#xD;
          -  7. in the past 6 months, the patients had arterial embolism diseases, such as angina,&#xD;
             MI, TIA, CVA, etc;&#xD;
&#xD;
          -  8. have received other types of anti-tumor or experimental treatment;&#xD;
&#xD;
          -  9. the patients are pregnant or lactating women;&#xD;
&#xD;
          -  10. patients with other diseases or mental disorders may affect their participation in&#xD;
             this study;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yiming Zhao, M.D.</last_name>
    <phone>+8618600490721</phone>
    <phone_ext>18600490721</phone_ext>
    <email>iammike0721@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aiwen Wu, M.D.</last_name>
    <phone>+8613911577190</phone>
    <email>wuaw@hsc.pku.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yiming Zhao, M.D.</last_name>
      <phone>+8618600490721</phone>
      <email>liyingjiedr@sina.com</email>
    </contact>
    <investigator>
      <last_name>Aiwen Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 23, 2020</study_first_submitted>
  <study_first_submitted_qc>May 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>October 11, 2020</last_update_submitted>
  <last_update_submitted_qc>October 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Aiwen Wu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectum cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

